Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma -: Results of a prospective Randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

被引：0
|
作者：
Hiddemann, W
Dreyling, MH
Forstpointner, R
Kneba, M
Woermann, B
Lengfelder, E
Schmits, R
Reiser, M
Metzner, B
Schmitz, N
Truemper, L
Eimermacher, H
Parwaresch, R
机构：
[1] Univ Munich, Hosp Grosshadern, Dept Internal Med 3, D-80539 Munich, Germany
[2] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany
[3] Hosp Braunschweig, Dept Internal Med, Braunschweig, Germany
[4] Univ Heidelberg, Hosp Mannheim, Dept Internal Med 3, D-6900 Heidelberg, Germany
[5] Univ Hosp Homburg Saar, Dept Internal Med 1, Homburg, Germany
[6] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[7] Hosp Oldenburg, Dept Internal Med 2, Oldenburg, Germany
[8] Gen Hosp St Georg, Dept Internal Med, Hamburg, Germany
[9] Univ Hosp Goettingen, Dept Internal Med, Gottingen, Germany
[10] St Marien Hosp, Dept Med, Hagen, Germany
[11] Univ Hosp Schleswig Holstein, Dept Hematopathol, Kiel, Germany
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
352
引用
收藏
页码：104A / 104A
页数：1
相关论文
共 50 条
  • [21] The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial
    Hoster, Eva
    Unterhalt, Michael
    Woermann, Bernhard
    Duehrsen, Ulrich
    Metzner, Bernd
    Eimermacher, Hartmut
    Neubauer, Andreas
    Wandt, Hannes
    Steinhauer, Hjalmar
    Martin, Sonja
    Heidemann, Else
    Aldrioud, Ali
    Hiddemann, Wolfgang
    Dreyling, Martin
    BLOOD, 2008, 112 (11) : 1048 - 1048
  • [22] Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    Hiddemann, W
    Kneba, M
    Dreyling, M
    Schmitz, N
    Lengfelder, E
    Schmits, R
    Reiser, M
    Metzner, B
    Harder, H
    Hegewisch-Becker, S
    Fischer, T
    Kropff, M
    Reis, HE
    Freund, M
    Wörmann, B
    Fuchs, R
    Planker, M
    Schimke, J
    Eimermacher, H
    Trümper, L
    Aldaoud, A
    Parwaresch, R
    Unterhalt, M
    BLOOD, 2005, 106 (12) : 3725 - 3732
  • [23] Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months.
    Buske, Christian
    Hoster, Eva
    Dreyling, Martin
    Forstpointner, Roswitha
    Kneba, Michael
    Schmitz, Norbert
    Schmits, Rudolf
    Metzner, Bernd
    Reiser, Marcel
    Lengfelder, Eva
    Woermann, Bernhard J.
    Harder, Harriet
    Hegewisch-Becker, Susanna
    Berdel, Wolfgang E.
    Hess, Georg
    Eimermacher, Hartmut
    Aldaoud, Ali
    Planker, Manfred
    Unterhalt, Michael
    Hiddemann, Wolfgang
    BLOOD, 2008, 112 (11) : 901 - 901
  • [24] Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG)
    Buske, Christian
    Hoster, Eva
    Dreyling, Martin H.
    Forstpointner, Roswitha
    Kneba, Michael
    Schmitz, Norbert
    Schmits, Rudolf
    Metzner, Bernd
    Hallek, Michael
    Lengfelder, Eva
    Hiddemann, Wolfgang
    Unterhalt, Michael
    BLOOD, 2009, 114 (22) : 1427 - 1427
  • [25] Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo
    Bastos-Oreiro, Mariana
    Gutierrez, Antonio
    Cabero Martinez, Almudena
    Lopez Jimenez, Javier
    Villafuerte Gutierrez, Paola Sandra
    Jimenez-Ubieto, Ana
    De la Fuente, Adolfo
    Navarro, Belen
    Stefania Infante, Maria
    Cordoba, Raul
    Perez De Oteyza, Jaime
    Gonzalez de Villambrosia, Sonia
    Del Campo, Raquel
    Garcia, Daniel
    Salar, Antonio
    Sancho, Juan-Manuel
    BLOOD, 2022, 140 : 3618 - 3619
  • [26] MCP (Mitoxantrone/Chlorambucil/Prednisolone) chemotherapy impairs the subsequent collection of stem cells in comparison to CHOP induction in patients with indolent lymphomas -: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG).
    Nickenig, C
    Dreyling, M
    Hoster, E
    Pfreundschuh, M
    Truemper, L
    Reiser, M
    Wandt, H
    Unterhalt, M
    Hiddemann, W
    BLOOD, 2005, 106 (11) : 931A - 931A
  • [27] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis
    Pouyiourou, M.
    Meyer, A.
    Stroux, A.
    Viardot, A.
    La Rosee, P.
    Maschmeyer, G.
    Kaempfe, D.
    Kahl, C.
    Vucinic, V.
    Monecke, A.
    Hirt, C.
    Weber, T.
    Meissner, J.
    Witzens-Harig, M.
    Boettcher, S.
    Schmalenberg, H.
    Marks, R.
    Prange-Krex, G.
    Kroschinsky, F.
    Hauf, E.
    Keller, U.
    Koch, K.
    Klapper, W.
    Herold, M.
    Scholz, Christian W.
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2821 - 2829
  • [28] First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis
    M. Pouyiourou
    A. Meyer
    A. Stroux
    A. Viardot
    P. La Rosée
    G. Maschmeyer
    D. Kämpfe
    C. Kahl
    V. Vucinic
    A. Monecke
    C. Hirt
    T. Weber
    J. Meissner
    M. Witzens-Harig
    S. Böttcher
    H. Schmalenberg
    R. Marks
    G. Prange-Krex
    F. Kroschinsky
    E. Hauf
    U. Keller
    K. Koch
    W. Klapper
    M. Herold
    Christian W. Scholz
    Annals of Hematology, 2020, 99 : 2821 - 2829
  • [29] Rituximab maintenance prolongs response duration after salvage therapy with R-FCM in patients with relapsed follicular lymphomas and mantle cell lymphomas:: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
    Hiddemann, W
    Forstpointner, R
    Dreyling, M
    Gramatzki, M
    Böck, HP
    Hanel, M
    Seymour, J
    Planker, M
    Dührsen, U
    Wilms, K
    Clemens, M
    Ludwig, WD
    Wandt, H
    Pasold, R
    Unterhalt, M
    BLOOD, 2005, 106 (11) : 270A - 270A
  • [30] Treatment of Early Stage Nodal Follicular Lymphoma Using Involved-Field Radiotherapy and Rituximab: Preliminary Results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG))
    Herfarth, Klaus
    Engelhard, Marianne
    Borchmann, Peter
    Hohloch, Karin
    Budach, Volker
    Viardot, Andreas
    Witzens-Harig, Mathias
    Eich, Hans
    Hiddemann, Wolfgang
    Dreyling, Martin
    BLOOD, 2012, 120 (21)
12345